Studying mirvetuximab combos for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous type.
- Your cancer must have a certain protein called FRα on at least 50% of its cells (tested on a piece of your tumor).
- You must be well enough to do daily activities (ECOG score 0 or 1).
- Your cancer must have responded to platinum-based chemo before and then come back after at least 6 months (platinum-sensitive).
- You cannot have had the study drug mirvetuximab or any similar drug before.
- You cannot have had more than 2 prior lines of chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.